To validate whether MAPT-IT1 and GATA3-AS1 are associated with resistance (RD) to NAC in luminal tumors, we performed a differential gene expression analysis comparing RD patients and pCR patients from GSE123845 and GSE163882 cohorts (Figure 7A,B), and their overexpression was validated in an independent cohort of 20 Hispanic luminal breast cancer patients (GSE270967, Figure 7C,D). The gene discussed is GATA3; the disease is breast carcinoma.